177 related articles for article (PubMed ID: 33417061)
1. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine.
Janssen JM; Jacobs BAW; Roosendaal J; Derissen EJB; Marchetti S; Beijnen JH; Huitema ADR; Dorlo TPC
AAPS J; 2021 Jan; 23(1):23. PubMed ID: 33417061
[TBL] [Abstract][Full Text] [Related]
2. Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.
Derissen EJ; Jacobs BA; Huitema AD; Rosing H; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2016 May; 81(5):949-57. PubMed ID: 26718616
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
Schmulenson E; Krolop L; Simons S; Ringsdorf S; Ko YD; Jaehde U
Cancer Chemother Pharmacol; 2020 Sep; 86(3):435-444. PubMed ID: 32852627
[TBL] [Abstract][Full Text] [Related]
4. Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.
Molenaar-Kuijsten L; Jacobs BAW; Kurk SA; May AM; Dorlo TPC; Beijnen JH; Steeghs N; Huitema ADR
Cancer Med; 2021 Jul; 10(14):4781-4789. PubMed ID: 34121365
[TBL] [Abstract][Full Text] [Related]
5. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil.
Derissen EJ; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2015 Jun; 110():58-66. PubMed ID: 25804433
[TBL] [Abstract][Full Text] [Related]
6. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
[TBL] [Abstract][Full Text] [Related]
7. Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
Paule I; Tod M; Hénin E; You B; Freyer G; Girard P
Cancer Chemother Pharmacol; 2012 Feb; 69(2):447-55. PubMed ID: 21809035
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
9. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Jacobs BAW; Deenen MJ; Joerger M; Rosing H; de Vries N; Meulendijks D; Cats A; Beijnen JH; Schellens JHM; Huitema ADR
CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):940-950. PubMed ID: 31652031
[TBL] [Abstract][Full Text] [Related]
11. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
Kobuchi S; Yazaki Y; Ito Y; Sakaeda T
Eur J Pharm Sci; 2018 Jan; 112():152-158. PubMed ID: 29175408
[TBL] [Abstract][Full Text] [Related]
12. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
[TBL] [Abstract][Full Text] [Related]
14. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
King TL; Voon PJ; Yuen KH; Mohamed Noor DA
Support Care Cancer; 2024 May; 32(6):345. PubMed ID: 38743316
[TBL] [Abstract][Full Text] [Related]
15. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A; Sharma A; Bakhshi S; Kumar A; Sharma V; Malik PS; Pramanik R; Gogia A; Prasad CP; Sehgal T; Gund S; Dev A; Cheung WY; Pandey RM; Kumar S; Gupta I; Batra A;
J Clin Oncol; 2024 May; 42(15):1821-1829. PubMed ID: 38412399
[TBL] [Abstract][Full Text] [Related]
16. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Chao YL; Anders CK
Clin Breast Cancer; 2018 Jun; 18(3):e301-e304. PubMed ID: 28899623
[No Abstract] [Full Text] [Related]
17. The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome.
Chen M; Chen J; Peng X; Xu Z; Shao J; Zhu Y; Li G; Zhu H; Yang B; Luo P; He Q
Environ Toxicol Pharmacol; 2017 Jan; 49():81-88. PubMed ID: 27951409
[TBL] [Abstract][Full Text] [Related]
18. Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen.
Naito M; Yamamoto T; Hara S; Shimamoto C; Miwa Y
Chemotherapy; 2017; 62(1):23-29. PubMed ID: 27229894
[TBL] [Abstract][Full Text] [Related]
19. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
Scontre VA; Martins JC; de Melo Sette CV; Mutti H; Cubero D; Fonseca F; Del Giglio A
J Diet Suppl; 2018 Sep; 15(5):606-612. PubMed ID: 29095653
[TBL] [Abstract][Full Text] [Related]
20. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]